142 related articles for article (PubMed ID: 23628404)
1. UPEC biomimickry at the urothelial barrier: lectin-functionalized PLGA microparticles for improved intravesical chemotherapy.
Neutsch L; Wambacher M; Wirth EM; Spijker S; Kählig H; Wirth M; Gabor F
Int J Pharm; 2013 Jun; 450(1-2):163-76. PubMed ID: 23628404
[TBL] [Abstract][Full Text] [Related]
2. Synergistic targeting/prodrug strategies for intravesical drug delivery--lectin-modified PLGA microparticles enhance cytotoxicity of stearoyl gemcitabine by contact-dependent transfer.
Neutsch L; Wirth EM; Spijker S; Pichl C; Kählig H; Gabor F; Wirth M
J Control Release; 2013 Jul; 169(1-2):62-72. PubMed ID: 23588390
[TBL] [Abstract][Full Text] [Related]
3. LogP of N-acyl-gemcitabine and lectin-corona emerge as key parameters in nanoparticulate intravesical cancer therapy.
Anzengruber M; Wimmer L; Szuchar R; Skoll K; Wirth M; Gabor F
Eur J Pharm Sci; 2023 Jan; 180():106330. PubMed ID: 36379358
[TBL] [Abstract][Full Text] [Related]
4. Poly - (l) - glutamic acid drug delivery system for the intravesical therapy of bladder cancer using WGA as targeting moiety.
Apfelthaler C; Anzengruber M; Gabor F; Wirth M
Eur J Pharm Biopharm; 2017 Jun; 115():131-139. PubMed ID: 28237713
[TBL] [Abstract][Full Text] [Related]
5. Biomimetic delivery strategies at the urothelium: targeted cytoinvasion in bladder cancer cells via lectin bioconjugates.
Neutsch L; Eggenreich B; Herwig E; Marchetti-Deschmann M; Allmaier G; Gabor F; Wirth M
Pharm Res; 2014 Mar; 31(3):819-32. PubMed ID: 24366662
[TBL] [Abstract][Full Text] [Related]
6. Combinatorial and sequential delivery of gemcitabine and oseltamivir phosphate from implantable poly(d,l-lactic-co-glycolic acid) cylinders disables human pancreatic cancer cell survival.
Allison Logan S; Brissenden AJ; Szewczuk MR; Neufeld RJ
Drug Des Devel Ther; 2017; 11():2239-2250. PubMed ID: 28814832
[TBL] [Abstract][Full Text] [Related]
7. A doxorubicin loaded colloidal delivery system for the intravesical therapy of non-muscle invasive bladder cancer using wheat germ agglutinin as targeter.
Apfelthaler C; Skoll K; Ciola R; Gabor F; Wirth M
Eur J Pharm Biopharm; 2018 Sep; 130():177-184. PubMed ID: 29960015
[TBL] [Abstract][Full Text] [Related]
8. Lectin bioconjugates trigger urothelial cytoinvasion--a glycotargeted approach for improved intravesical drug delivery.
Neutsch L; Eggenreich B; Herwig E; Marchetti-Deschmann M; Allmaier G; Gabor F; Wirth M
Eur J Pharm Biopharm; 2012 Oct; 82(2):367-75. PubMed ID: 22889683
[TBL] [Abstract][Full Text] [Related]
9. In vitro study of anticancer drug doxorubicin in PLGA-based microparticles.
Lin R; Shi Ng L; Wang CH
Biomaterials; 2005 Jul; 26(21):4476-85. PubMed ID: 15701377
[TBL] [Abstract][Full Text] [Related]
10. Biocompatible gemcitabine-based nanomedicine engineered by Flow Focusing for efficient antitumor activity.
Martín-Banderas L; Sáez-Fernández E; Holgado MÁ; Durán-Lobato MM; Prados JC; Melguizo C; Arias JL
Int J Pharm; 2013 Feb; 443(1-2):103-9. PubMed ID: 23299085
[TBL] [Abstract][Full Text] [Related]
11. Biological evaluation of 5-fluorouracil nanoparticles for cancer chemotherapy and its dependence on the carrier, PLGA.
Nair K L; Jagadeeshan S; Nair SA; Kumar GS
Int J Nanomedicine; 2011; 6():1685-97. PubMed ID: 21980233
[TBL] [Abstract][Full Text] [Related]
12. Glycan-mediated uptake in urothelial primary cells: Perspectives for improved intravesical drug delivery in urinary tract infections.
Pichl CM; Feilhauer S; Schwaigerlehner RM; Gabor F; Wirth M; Neutsch L
Int J Pharm; 2015 Nov; 495(2):710-8. PubMed ID: 26383837
[TBL] [Abstract][Full Text] [Related]
13. Stereocomplex Prodrugs of Oligo(lactic acid)
Tam YT; Huang C; Poellmann M; Kwon GS
ACS Nano; 2018 Jul; 12(7):7406-7414. PubMed ID: 29957934
[TBL] [Abstract][Full Text] [Related]
14. Synthesis, characterization and mechanistic-insight into the anti-proliferative potential of PLGA-gemcitabine conjugate.
Khare V; Kour S; Alam N; Dubey RD; Saneja A; Koul M; Gupta AP; Singh D; Singh SK; Saxena AK; Gupta PN
Int J Pharm; 2014 Aug; 470(1-2):51-62. PubMed ID: 24810239
[TBL] [Abstract][Full Text] [Related]
15. BSA-PLGA-based core-shell nanoparticles as carrier system for water-soluble drugs.
Chitkara D; Kumar N
Pharm Res; 2013 Sep; 30(9):2396-409. PubMed ID: 23756758
[TBL] [Abstract][Full Text] [Related]
16. Gemcitabine loaded biodegradable PLGA nanospheres for in vitro pancreatic cancer therapy.
Jaidev LR; Krishnan UM; Sethuraman S
Mater Sci Eng C Mater Biol Appl; 2015 Feb; 47():40-7. PubMed ID: 25492170
[TBL] [Abstract][Full Text] [Related]
17. Enhanced taxane uptake into bladder tissues following co-administration with either mitomycin C, doxorubicin or gemcitabine: association to exfoliation processes.
Pandey R; Jackson JK; Liggins R; Mugabe C; Burt HM
BJU Int; 2018 Nov; 122(5):898-908. PubMed ID: 29862643
[TBL] [Abstract][Full Text] [Related]
18. EGFR targeted PLGA nanoparticles using gemcitabine for treatment of pancreatic cancer.
Aggarwal S; Yadav S; Gupta S
J Biomed Nanotechnol; 2011 Feb; 7(1):137-8. PubMed ID: 21485840
[TBL] [Abstract][Full Text] [Related]
19. Thermosensitive polymer prodrug nanoparticles prepared by an all-aqueous nanoprecipitation process and application to combination therapy.
Guerassimoff L; Ferrere M; Van Herck S; Dehissi S; Nicolas V; De Geest BG; Nicolas J
J Control Release; 2024 May; 369():376-393. PubMed ID: 38554772
[TBL] [Abstract][Full Text] [Related]
20. Hyaluronic acid-coated, prodrug-based nanostructured lipid carriers for enhanced pancreatic cancer therapy.
Lu Z; Su J; Li Z; Zhan Y; Ye D
Drug Dev Ind Pharm; 2017 Jan; 43(1):160-170. PubMed ID: 27553814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
